UCB SA (UNC.F)
| Previous close | 126.00 |
| Open | 126.65 |
| Bid | 127.40 x 30700 |
| Ask | 129.90 x 30700 |
| Day's range | 126.65 - 126.65 |
| 52-week range | 65.68 - 129.15 |
| Volume | |
| Avg. volume | 90 |
| Market cap | 24.415B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 71.96 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.36 (1.07%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 This article represents the primary publication of BIMZELX data from the two pivotal Phase 3 HS studies. HS is one of the most burdensome, chronic, systemic, inflammatory s
- PR Newswire
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
- PR Newswire
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
